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Quality of Life in Substance Use Disorder patients with and without Attention Deficit Hyperactivity 
Disorder 12 months after treatment:  a naturalistic follow-up study 
 
 
     Abstract 
Background. There is sparse research on quality of life (QoL) as an outcome measure in patients with substance use 
disorders (SUD), with or without attention deficit hyperactivity disorder (ADHD). We aimed to investigate whether 
SUD patients with and without ADHD (SUD+ADHD vs. SUD-ADHD) differed in QoL at baseline and  at a12- 
month follow-up after SUD treatment. The groups were additionally compared with data from a national population 
sample (NPS). Methods. From a sample of 16 SUD+ADHD and 87 SUD-ADHD patients originally recruited 
between 2010 and 2012, eight SUD+ADHD (50.0%) and 28 SUD-ADHD (32.2%) patients were reached at follow-
up. QoL was measured with the short version of the World Health Organization QoL instrument (WHOQOL-BREF). 
Cross- sectional data on QoL from NPS was utilized. Results. Compared to NPS, SUD patients reported significantly 
lower QoL at baseline and follow-up. Furthermore, QoL was similar at baseline in SUD+ADHD and SUD-ADHD 
patients. At a 12-month follow-up after SUD treatment, SUD+ADHD patients ‘ QoL had improved, however not 
significantly differing from SUD-ADHD patients or the NPS. SUD-ADHD patients’ QoL remained significantly 
lower. Conclusions. At follow-up, SUD+ADHD patients’ QoL improved nominally compared to SUD-ADHD 
patients, but not the NPS. The clinical and functional relevance of these findings should be investigated further.  
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Quality of Life in Substance Use Disorder patients with and without Attention Deficit Hyperactivity 
Disorder 12 months after treatment:  a naturalistic follow-up study 
 
Substance use disorders are defined by cravings, tolerance, withdrawal symptoms, and a compulsive 
substance seeking despite the devastating consequences at physical, psychological, interpersonal, and societal levels 
(American Psychiatric Association, 2013; Volkow & Baler, 2014). Adults seeking substance use disorder (SUD) 
treatment frequently present with attention deficit hyperactivity disorder (ADHD) as a co-occurring condition (5–
31%) (van de Glind et al., 2014). ADHD is a neurodevelopmental disorder encompassing the core symptoms of 
inattention, hyperactivity, and impulsivity (American Psychiatric Association, 2013). Both disorders have similar 
difficulties, including impulsive decision-making and reward deficits (Ortal et al., 2015). In addition, individuals 
with SUD may present symptoms resembling those of ADHD, including states of  intoxication or withdrawal (Levin, 
2007). Other mental conditions in SUD (e.g., bipolar disorder, anxiety and personality disorders) may present 
symptoms similar to those of ADHD (Fatseas, Debrabant, & Auriacombe, 2012). Such matters make the assessment 
and diagnosis of ADHD difficult in SUD populations (Crunelle et al., 2018). Furthermore, individuals with SUD 
who have also been diagnosed with ADHD (SUD+ADHD) challenge SUD treatment because they transition more 
rapidly and more severely from substance use (SU) to SUD (Kim et al., 2006; Moura et al., 2013), drop-out of SUD 
treatment earlier (Levin et al., 2004), and are more frequently afflicted with other psychiatric disorders (van 
Emmerik-van Oortmerssen et al., 2014) than  are SUD patients without ADHD. 
Increasingly investigated as a secondary outcome measure in health care research (Brod, Johnston, Able, & 
Swindle, 2006; Coghill, 2010; Laudet, 2011; Picci et al., 2014), the construct of quality of life (QoL) is defined as 
how we experience our circumstances, goals, and interests in life, based on the value system and cultural context in 
which we live (The WHOQOL Group, 1998). As the complexity associated with SUD plus ADHD affects 
individuals in nearly all life domains (Gjervan, Torgersen, & Hjemdal, 2016; Uchida, Spencer, Faraone, & 
Biederman, 2015; Umar, Salihu, & Owolabi, 2017), interventions targeting this group of patients should aim to 
improve their QoL. 
When compared cross-sectionally, SUD+ADHD and SUD-ADHD patients seem to have no differences in 
QoL (Kronenberg, Goossens, van Etten, van Achterberg, & van den Brink, 2015). However, to our knowledge only 
one study has prospectively (two months after treatment) considered the QoL of these individuals (without a 
comparison group) (van Emmerik-van Oortmerssen et al., 2019). That study found that the ADHD symptoms among 
SUD+ADHD individuals had improved but there were no changes in QoL. There is evidence that improved QoL in 
ADHD is associated with psychopharmacological treatment (e.g., Agarwal, Goldenberg, Perry, & IsHak, 2012). 
Therefore,  the QoL in SUD+ADHD patients  may benefit from such treatment as well. Naturalistic follow-up 
studies concerning QoL in SUD+ADHD patients are still scarce. Such studies may contribute to the literature by 
identifying factors that improve the QoL of SUD+ADHD patients, which can be integrated into SUD treatment. For 
these reasons we were interested in investigating the following in the present naturalistic study: 
1. To compare the QoL of SUD patients at baseline and at a 12- month follow-up after SUD treatment with 
cross-sectional data from a national population sample.   
2. To investigate whether there were differences in QoL between SUD+ADHD and SUD-ADHD patients at 
baseline and follow-up. 
     Materials and Methods 
 Participants 
Sixteen SUD+ADHD and 87 SUD-ADHD participants signed an informed consent form at the University 
Hospital of Northern Norway (between February 2010 and July 2012). Ethical approval was granted by regional 
committees for medical and health research ethics, REK sør-øst B, 2009/1355b. Study participants were followed up 
at three points after SUD treatment (at three, six and 12 months, as shown in Figure 1). The present study reports on 
36 SUD patients, eight SUD+ADHD patients and 28 SUD-ADHD patients (34.9% of the original sample of 103 
patients), who were reached at the longest observation time available, the 12-month follow-up, (hereafter referred to 
as “follow-up”).This is because although some improvements in QoL have been observed as early as six months 
after SUD treatment (Pasareanu, Opsal, Vederhus, Kristensen, & Clausen, 2015), studies indicate that QoL reaches 
stability in one to two years after addiction treatment, granted considerable substance reduction or abstinence (Chou 
et al., 2013; Daeppen et al., 2014; Laudet, 2011).  Furthermore, because psychopharmacological treatment is 
associated with improved QoL in ADHD (Agarwal et al., 2012), we report the psychopharmacological treatment 
status of SUD+ADHD individuals reached at the longest observation time. Additional information about recruitment 
and patient characteristics is presented in Flores-Garcia, Ytterstad, Lensing, and Eisemann (2016). 
 
The self-reported QoL of the two SUD patient groups were compared against QoL data from a national 
population sample (NPS), reported in a cross-sectional study by Mathiesen and colleagues (2012). This study 
consisted of 1,230 randomly selected adults drawn from the Norwegian National Register. 
 Procedure 
The study participants, all of whom had previously received detoxification treatment, were assessed during 
an SUD treatment of about two months. Baseline assessements were commonly completed one to three weeks after 
initiation of SUD treatment. Follow-ups were conducted either by outpatient services (i.e., via telephone, postal mail, 
home visits, or with the assistance of a contact person chosen by the participant from his/her local public support 
system) or by one-week inpatient readmissions. Depending on time constraints, these follow-up assessments were 
conducted either by the clinician with whom the study participant had collaborated most frequently or by the first 
author (LF). It was not always feasible for participants to adhere to the original follow-up schedule. In such cases, 
delays of up to two months were allowed. All participants were offered reading and writing assistance. 
 ADHD diagnosis and pharmacological treatment 
According to the national guideline on ADHD (Norwegian Directorate for Health and Social Affairs, 2007), 
the assessment and diagnosis of ADHD in adults (International Classification of  Diseases 10
th
 revision, ICD-10) 
involves the assessment of impairment in childhood and adulthood (i.e., the extent to which the ADHD symptoms 
have affected functioning in the different life domains), assessment of concurrent psychopathology and differential 
diagnosis, and collection of collateral information from the individual’s parents and other relevant informants. This 
procedure must be conducted by authorized healthcare practitioners (physicians/psychologists). Information about 
those participants  fulfilling the criteria for an ADHD diagnosis was extracted from their medical records. The eight 
SUD+ADHD patients  (mean age at baseline 41.5 ± 7.9; age range 30-50) reached at follow-up were all assessed in 
their adulthood (mean age at assessment 36.5± 11.5, age range 18-50). The time from diagnosis to entering the study 
at baseline was 4.0± 4.4 years. At baseline, five of the eight SUD+ADHD patients had recently started 
psychopharmacological treatment with methylphenidate (MPH). 
  
Baseline characteristics and re-assessment at follow-up 
As previously reported, at baseline, SUD+ADHD patients were younger, showed more severe ADHD 
symptomatology, more amphetamine addiction and self-reported less alcohol use than SUD-ADHD patients (Flores-
Garcia et al., 2016). In this study, the eight SUD+ADHD and 28 SUD-ADHD patients were compared regarding 
QoL, ADHD symptoms and SUD symptoms at baseline and follow-up. 
 
Measures 
At baseline, DSM-IV Axis I current comorbid disorders were assessed by the Mini International 
Neuropsychiatric Interview (M.I.N.I. PLUS) (Sheehan et al., 1994). Axis II disorders were assessed by the 
Structured Clinical Interview for DSM-IV (SCID II, First, Spitzer, Gibbon, Williams, & Benjamin, 1995), but only 
when the treatment staff considered it necessary. 
 SUD patients were assessed for QoL, ADHD symptoms and substance use at baseline and follow-up. A 
brief description of the instruments used is presented below. 
QoL was assessed using the World Health Organization questionnaire, short version (WHOQOL-BREF), 
which consists of 26 items measuring four QoL domains: physical health (domain 1); psychological health (domain 
2); social relationships (domain3) and environment (domain 4) (Mathiesen et al., 2012; The WHOQOL Group, 
1998).  Answer alternatives are on a five-point Likert scale varying from 1 (lowest) to 5 (highest). Elevated scores 
indicate better QoL. In the NPS, the internal consistency reliability (Cronbach’s α) ranged from 0.63 (domain 3) to 
0.84 (domains 1 and 2) (Mathiesen et al., 2012). In this study, baseline Cronbach’s α coefficients ranged from 0.71 
(domain 3) to 0.84 (domain 4) and at follow-up from 0.68 (domain 3) to 0.89 (domain 2). A systematic review and 
meta-analysis showed that WHOQOL-BREF is able to detect meaningful changes in QoL across different patient 
populations even though when they are small (Skevington & Epton, 2018). 
The adult ADHD Self-Report Scale (ASRS) measures the frequency of experiencing the core ADHD 
symptoms of inattention and hyperactivity/impulsivity are experienced (Kessler et al., 2005). The 18 items 
comprising the ASRS are divided into parts A and part B. Answer alternatives range from 0 (never)  to 4 (very 
often). High scores indicate high symptom severity. Part A is a six-item scale that covers the most predictive 
symptoms of ADHD, whereas part B covers additional symptoms associated with  the clinical picture of ADHD 
(Kessler et al., 2007; Taylor, Deb, & Unwin, 2011). The ASRS part A is frequently used in studies aiming to identify 
individuals who potentially have ADHD in SUD populations (e.g., van de Glind et al., 2013). In general, the cut-off 
score recommended to carry a full assessment of ADHD is ≥14. A recent study specifically performed in SUD 
populations recommended a lower cut-off  score of ≥ 11(Luderer et al., 2018) to gain adequate sensitivity for ADHD 
in SUD. In the present study, part A and part B of the ASRS were analyzed to elucidate changes from baseline to 
follow-up in the additional symptom burden of those diagnosed with SUD+ADHD, as compared to SUD-ADHD 
patients. Cronbach’s α coefficients reported previously for part A and part  B of the ASRS were 0.86 and 0.93, 
respectively (Flores-Garcia et al., 2016). In this study, the Cronbach’s α coefficients for part A and part B were 0.86 
and 0.90 at the baseline and 0.84 and 0.86 at follow-up, respectively. 
Self-reported alcohol use was measured by the screening instrument Alcohol Use Disorder Identification 
Test (AUDIT) (Babor, Higgins-Biddle, Saunders, & Monteiro, 2001) based on the DSM-IV diagnostic criteria for 
SUD (American Psychiatric Association, 1994), consists of ten questions, and answer alternatives vary from 0 
(never)  to 4 (daily). The maximum possible score is 40. Scores >8 indicate risk of  harmful drinking, scores >16 
indicate medium level of drinking harmfully, and scores >20 indicate excessive drinking (Saunders, Aasland, Babor, 
de la Fuente, & Grant, 1993). AUDIT has previously shown an internal consistency coefficient of 0.77 (Rumpf, 
Wohlert, Freyer-Adam, Grothues, & Bischof, 2013), compared to 0.94 at both observation times in this study. 
The screening instrument Drug Use Disorder Identification Test (DUDIT), consisting of 11 questions 
measured non-alcohol SU (Berman, Bergman, Palmstierna, & Schlyter, 2005). Similar to the AUDIT, the answer 
alternatives in the DUDIT range from 0 (never) to 4 (daily). The maximum score is 44. Scores >2 for women and >6 
for men are considered problematic use, whereas scores >25 indicate substance addiction (Berman et al., 2005). The 
DUDIT has shown Cronbach’s α coefficients of 0.90 (Hildebrand, 2015). In this study, they were 0.98 and 0.96 at 
the baseline and 12-month follow-up, respectively.  
 
Statistical analyses 
Survival analysis with the Cox proportional regression model was applied to all data (n=103) to locate possible 
factors explaining drop-outs at follow-up. Time in days from baseline until the date of drop-out, date of the 
individual 12 month follow-up appointment or death date, whichever came first, were recorded for all 103 SUD 
patients. Survival times for individuals not dropping out were recorded as censored, according to the terminology of 
survival analysis.  
Non-parametric Mann-Whitney U (scale variables) and Fisher’s exact tests (count variables) were chosen to 
compare the NPS and SUD groups due to the small size of the SUD+ADHD group. A one-sample U-test compared 
the SUD group with the NPS mean value, and the baseline to follow-up change. Two-sample U-test compared 
SUD+ADHD vs. SUD-ADHD. 
Due to the many statistical tests in this study, significant results were restricted to p-values below .01, 
whereas results below.05 were considered tendencies.  The statistical packages SPSS v.22 (IBM Corp., 2013) and the 
statistical computing language R (R Core Team, 2015) were used for the analyses. In particular, we utilized R-
functions: wilcox.test, fisher.test, glm, and coxph in the survival-package.  
     Results 
 Sociodemographic and Clinical Characteristics at Baseline and Follow-up 
Sociodemographic characteristics. The sample comprised 28 males and eight females aged between 28 and 
65 (Mean age 47.5 ± 9.6 years). When comparing the SUD groups with the NPS, three out of four SUD patients were 
men, while the gender ratio was nearly equal in the NPS. Individuals in the NPS were more often employed than in 
either SUD patient group. Additionally, NPS individuals were more likely to cohabitate and had more years of 
completed education than SUD-ADHD patients. The age differences between the NPS and SUD groups were not 
significant (Table 1).  
From baseline to follow-up, five male SUD-ADHD patients had died, of which the majority consumed 
multiple substances, predominantly alcohol. None of the SUD+ADHD patients had died at follow-up. A survival 
analysis of all 103 SUD patients at baseline (see flow chart) revealed that younger patients and those cohabitating 
with a partner had an increased likelihood of dropping out at follow-up compared to older SUD individuals and those 
with no cohabitant (HR=1.05, p=.001 and HR=2.5, p = .008, respectively). However, there were no significant 
differences between SUD+ADHD and SUD-ADHD patients concerning dropping out at follow-up. In the 
SUD+ADHD group, 50% of  the follow-up assessments were conducted through outpatient services and 50%  as 
inpatient readmissions. In the SUD-ADHD group, the corresponding proportions were 57.7% and 42.3%, 
respectively. 
Clinical characteristics.  At baseline five SUD+ADHD patients were recieving MPH. In our previous study 
we reported the baseline ASRS scores of the original samples of  SUD+ADHD and SUD-ADHD patients. In that 
study, SUD+ADHD patients showed significantly higher scores on parts A and  part B of the ASRS compared to 
SUD-ADHD patients (Flores-Garcia et al., 2016). In the present study, we also investigated whether the eight 
SUD+ADHD patients showed higher baseline ASRS scores on part A and part B compared to the 28 SUD-ADHD 
patients. As Table 2 shows, compared to SUD-ADHD patients, SUD+ADHD patients showed baseline tendencies 
(p<.05) toward a higher ADHD symptom frequency. The recommended cut-off score for ASRS part A for a further 
assessment  of ADHD is ≥14. For SUD populations recently an ASRS part A cut-off score of  ≥11 has been 
suggested (Kessler et al., 2007; Luderer et al., 2018; Taylor et al., 2011). As a reference, 75% in the SUD+ADHD 
group (already diagnosed as having ADHD) reported scores above the recommended cut-off score of  >=14 for the 
ASRS part A and 12.5% reported a cut-off of >= 11. Among the SUD-ADHD patients, the corresponding 
proportions were of 32.1% and 21.4%, respectively. SUD+ADHD patients also had higher rates of amphetamine 
SUD (p<.01) and less alcohol use (p<.05) than SUD-ADHD patients. Neither group differed statistically in baseline 
non-alcohol SU, or in other clinical variables. However, psychiatric comorbidity was more frequent among SUD-
ADHD patients.  
At follow-up, seven of the eight SUD+ADHD patients were treated with MPH. In terms of ADHD 
symptomatology, no statistical differences were observed between SUD+ADHD and SUD-ADHD patients (Table 2). 
Furthermore, at this observation point, 37.5% of the SUD+ADHD group still reported ASRS screener scores at the 
cut-off of ≥14 and 12.5.% had scores at a cut-off of ≥11. In the SUD-ADHD group, the corresponding proportions 
were 17.8% and 28.5%, respectively. In addition, the SUD groups reported reduced alcohol use, particularly SUD-
ADHD patients. The differences between SUD+ADHD and SUD-ADHD patients found at baseline (p<0.05), were 
non-significant at follow-up (see Table 2). 
 QoL at baseline and follow-up compared to the NPS 
Preliminarily, we compared the QoL of the SUD patients who were reached at the three-month and six-month 
follow-ups to the NPS. This, to verify that the results from a larger sample showed trends similar to the results from 
the sample reached at follow-up. The results from the three-and six months follow-ups were similar to those 
observed at baseline (data available on request). 
Comparisons in QoL between the SUD patients and the NPS are reported in Table 3 and Figure 2. SUD 
patients in total reported significantly lower QoL on all domains (p’s< .001) than the NPS at both observation times. 
SUD+ADHD patients reported a 3.6–5.0 lower average baseline QoL on all domains compared to the NPS, 
but this was non-significant in domain 3 (p=0.057) and only tendencies in domain 1, 2 and 4 (p=0.014). SUD-ADHD 
patients had significantly lower QoL at baseline in all domains (p’s<.000) compared to the NPS. 
At follow-up, score differences in QoL between SUD+ADHD patients and NPS were smaller (1.4–2.4) than 
those observed at baseline, and non-significant in all domains except in domain 1 physical health where there was 
still a tendency of lower QoL compared to NPS (p = .016). The QoL among SUD-ADHD patients was almost 
unchanged and still significantly lower than the NPS (Table 3 and  Figure 2). 
 The two SUD groups reported similarly low QoL (0.3-1.4 point’s difference) at baseline in all domains. 
From baseline to follow-up, only SUD+ADHD patients had a tendency of improved QoL which was present in 
domain 1, 2 and 4. However, the difference between the SUD groups at follow-up (0.8-1.7 point’s difference) 
remained non significant (physical health, p=.390; psychological health, p=.229; social relations, p=.213; and 
environment, p=.542) (Table 3 and Figure 2). 
Discussion  
The aims of the present study were (1) to compare the QoL of SUD patients both at baseline and at12- 
months follow-up after SUD treatment with cross-sectional data from a NPS and (2) to investigate whether there 
were differences in QoL between SUD+ADHD and SUD-ADHD patients at both the baseline and the follow-up. 
At both observation times, the SUD patients reported significantly lower QoL (all domains) than did the 
NPS. This is in line with results from studies comparing individuals with SUD (Tracy et al., 2012) and ADHD 
(Lensing, Zeiner, Sandvik, & Opjordsmoen, 2015) to the general population. The present results seem rational 
because for individuals with persistent disorders, such as SUD and ADHD, reaching a similar QoL as those in good 
general health may take substantial efforts at different levels. 
When the SUD group was investigated by ADHD status, at a tendency level (p<.05), SUD+ADHD patients 
showed improvements in QoL at follow-up. These improvements were observed specifically in domain 1 (physical 
health), domain 2 (psychological health) and domain 4 (environment). SUD-ADHD patients reported a nearly 
unchanged QoL from baseline to follow-up on all domains. Furthermore, five SUD+ADHD patients were treated 
with MPH at baseline and seven at follow-up. It is likely that those receiving MPH treatment at baseline would have 
reported a lower baseline QoL in the absence of MPH treatment, which would have meant larger differences in QoL 
at follow-up.  However, the small sample size limited  investigating this point further.  
A systematic review and meta-analysis indicated that WHOQOL-BREF detects clinically meaningful 
changes in QoL (Skevington & Epton, 2018). Therefore, we suggest that SUD+ADHD patients’ enhanced QoL is 
reliable and clinically relevant. Although the present study is substantially limited by its small sample sizes, 
particularly regarding the number of SUD+ADHD patients, it begins a discussion concerning the QoL over time of 
this patient group. The results may be explained either by issues specific to ADHD, such as reduced symptoms, 
reduced SUD symptoms or by more general issues associated with self-reporting. These possible explanations are 
considered in the following discussion. 
 There is scant research comparing the QoL of SUD+ADHD vs. SUD-ADHD populations. A longitudinal 
study of individuals with another complex comorbidity, bipolar disorder, both with and without SUD (Mazza et al., 
2009) reported no changes in QoL in both groups a year after treatment. In addition, there is little research comparing  
the QoL of individuals with ADHD with and without other psychiatric disorders. A longitudinal study in adolescents 
showed that ADHD symptoms and co-occurrent anxiety and depression symptoms  greatly affected  their QoL (Pan 
& Yeh, 2017). Findings from these studies on SUD or ADHD plus psychiatric comorbidity conflict with the present 
results, which show increased QoL scores among SUD+ADHD patients at follow-up. 
In the present study, most SUD+ADHD patients were diagnosed with an amphetamine SUD. Some studies 
of SUD+ADHD individuals with stimulant SUD have reported associations between central stimulant treatment and 
improved SUD and ADHD symptoms (Konstenius et al., 2014; Levin et al., 2015). Although those studies did not 
consider QoL, research on ADHD and SUD suggest that QoL increases as the symptoms of these disorders abate 
(Laudet, 2011; Picci et al., 2014). In ADHD, psychopharmacological treatment is also associated with symptom 
reduction and improved QoL (Agarwal et al., 2012). Based on this body of research, one interpretation of the present 
findings is that improvements in QoL and ADHD symptoms in SUD+ADHD patients, particularly in those with 
stimulant SUD, was associated with MPH treatment. Nevertheless, implying that psychopharmacological treatment 
reduces symptoms in SUD+ADHD individuals with a specific SUD may be an oversimplification of the complexity 
of SUD, as these individuals may not have a specific substance use pattern (Clure et al., 1999) or it may change over 
time. As for the SUD-ADHD group, the proposition that QoL changes in parallel with SUD symptoms (Laudet, 
2011) is challenged by the present finding that despite reporting less SU at follow-up, SUD-ADHD patients showed 
almost unchanged QoL.   
Studies suggest that specific ADHD symptoms are associated with QoL. For instance, severity of inattention 
seems to negatively affect QoL more than does hyperactivity/impulsivity (Weiss et al., 2010). Additionally, Gjervan, 
Torgersen, Rasmussen, and Nordahl (2014) posited that inattention was specifically related to the vitality and 
emotional aspects of QoL and that hyperactivity/impulsivity was  related to social functioning and mental health. In 
the present study, SUD+ADHD patients’ specific ADHD symptoms might have been associated with particular 
domains of QoL. However, it was not possible to test for associations between QoL and ADHD, nor could we 
investigate the potential effect of MPH on the QoL of SUD+ADHD patients. Such relationships should be further 
investigated in larger samples, using the same measurements to enable interpretation. An alternative interpretation is 
that because as individuals with ADHD tend to show positive appraisal bias (i.e., inflated self-perceptions) in self-
reports (Owens, Goldfine, Evangelista, Hoza, & Kaiser, 2007), it is possible that this phenomenon contributed 
SUD+ADHD patients’ enhanced QoL evaluations. Finally, a more general interpretation of the present findings may 
relate to the bias implicit in prospective studies on QoL (Blome & Augustin, 2015), including recalibration (i.e., 
understanding the questions differently when revisited) or to social desirability (i.e., seeing one-self in a positive 
light and seeking acceptance from others). Social desirability has been commonly observed in the self-reports of  
SUD individuals (Arab et al., 2014). Accordingly, due to recalibration, SUD+ADHD patients might have interpreted 
their QoL differently at follow-up compared to baseline. Additionally, due to social desirability, SUD+ADHD 
patients may have reported better QoL, believing that they were expected to show improvements at follow-up. 
However, as the SUD-ADHD patients’ QoL self-reports remained unchanged, it is difficult to attribute the present 
results to either response-shift bias or social desirability. 
It was not possible to determine clearly why SUD+ADHD patients reported higher QoL scores following 
SUD treatment, nor how exactly these improvements were meaningful for the patients. The need to prospectively 
investigate what SUD+ADHD patients consider essential to enrich their QoL is highlighted by these results. Future 
studies should be designed to ensure inclusion of a large sample size, the use of current guidelines and 
recommendations to diagnose ADHD in SUD patients, and special caution in the case of naturalistc studies, because 
of the many uncontrolled variables inherent in these type of studies. As a suggestion for clinical practice, 
determining SUD+ADHD patients’ baseline QoL, symptom severity, functional status, and associated goals during 
SUD treatment could lead to individualized interventions involving various forms of support. Subsequently, these 
interventions should be revisited in collaboration with the SUD+ADHD patients’ support systems.  
Limitations 
This study has several limitations, mostly related to its small sample size, which compromised statistical 
inference and limited the data analysis. First, although eight out of 16 SUD+ADHD patients were reached at follow-
up,overall, the retention rate was low (35%). Even though the survival analysis detected no specific variables 
explaining drop-out from the study by ADHD status, the samples still may have been biased. Second, women, 
individuals with greater symptom severity and psychiatric comorbidity, which is a characteristic consistently 
reported in this patient group (van Emmerik-van Oortmerssen et al., 2014) were underrepresented in the study. 
Consequently, the SUD+ADHD group might have had relatively better mental health than individuals in other 
studies. Relatedly, the findings from ASRS part A suggested some cases of subthreshold ADHD (Crunelle et al., 
2018), which we did not investigate. Third, the role of MPH treatment could not be investigated further. Fourth, the 
study lacked information on life-productivity/functionality outcomes (e.g., employment status, functionality in 
everyday tasks and goals), which is important to the QoL of adults with ADHD (Brod et al., 2006). Without 
information on patients’ functional outcomes, it was not possible to elucidate possible associations between 
improved QoL and functionality among SUD+ADHD patients. Fifth, in some cases, follow-ups were not conducted 
precisely as scheduled. Thus, the timing of the self-reported QoL was not the same for all SUD patients. Some 
patients might have had access to treatment for SUD/mental health problems or other types of healthcare support 
between discharge and follow-up. In such cases, this access may have exerted an important protective effect against 
SU and may have influenced the QoL self-reports of these individuals. Conversely, we did not gather systematic 
information on relapse rates at follow-up, which might have affected participants’ perception of QoL. Lastly, type of 
SUD treatment as a possible explanation for the present findings was outside the scope of the present study. 
 
Conclusions 
When assessing 12 months following treatment, SUD patients in general showed a lowered QoL compared 
to individuals in the general population. When divided by ADHD status, SUD+ADHD patients reported increased 
QoL scores from baseline to follow-up, which did not differ significantly from the NPS in most QoL domains. 
However, no statistical difference between SUD+ADHD vs. SUD-ADHD was observed at baseline nor at follow-up. 
Furthermore, SUD+ADHD patients reported a reduction (below cut-off) in ADHD symptoms as well as 
improvements in SUD symptoms. In spite of  reporting a reduction in SUD symptoms at follow-up, SUD-ADHD 
patients’ QoL remained unchanged, significantly differing from the NPS at both observation times. It was unclear 
whether factors associated with ADHD played a role in how SUD+ADHD patients evaluated their QoL. Determining 
whether SUD+ADHD patients’ improvements in QoL are clinically meaningful should be complemented by 
information about patients’ functional outcomes.  
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